Cite
Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer.
MLA
Xing, Puyuan, et al. “Real World Study of the Continuation of Bevacizumab beyond Disease Progression after First‐line Treatment Containing Bevacizumab in Chinese Patients with Advanced Non‐small Cell Lung Cancer.” Thoracic Cancer, vol. 9, no. 12, Dec. 2018, pp. 1716–24. EBSCOhost, https://doi.org/10.1111/1759-7714.12886.
APA
Xing, P., Mu, Y., Wang, Y., Hao, X., Zhu, Y., Hu, X., Wang, H., Liu, P., Lin, L., Wang, Z., & Li, J. (2018). Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer. Thoracic Cancer, 9(12), 1716–1724. https://doi.org/10.1111/1759-7714.12886
Chicago
Xing, Puyuan, Yuxin Mu, Yan Wang, Xuezhi Hao, Yixiang Zhu, Xingsheng Hu, Hongyu Wang, et al. 2018. “Real World Study of the Continuation of Bevacizumab beyond Disease Progression after First‐line Treatment Containing Bevacizumab in Chinese Patients with Advanced Non‐small Cell Lung Cancer.” Thoracic Cancer 9 (12): 1716–24. doi:10.1111/1759-7714.12886.